Laman Utama4547 • TYO
add
Kissei Pharmaceutical Co Ltd
Tutup sebelumnya
¥3,655.00
Julat hari
¥3,620.00 - ¥3,680.00
Julat tahun
¥3,000.00 - ¥4,270.00
Permodalan pasaran
173.92B JPY
Bilangan Purata
117.57K
Nisbah P/E
13.67
Hasil dividen
2.37%
Pertukaran utama
TYO
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (JPY) | Dis 2024info | Perubahan T/T |
|---|---|---|
Hasil | 23.20B | 11.12% |
Perbelanjaan pengendalian | 9.26B | 14.14% |
Pendapatan bersih | 3.59B | 35.05% |
Margin untung bersih | 15.48 | 21.60% |
Pendapatan bagi setiap syer | — | — |
EBITDA | 3.52B | 10.84% |
Kadar cukai berkesan | 18.37% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (JPY) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 44.46B | 2.90% |
Jumlah aset | 248.93B | 8.96% |
Jumlah liabiliti | 37.61B | 21.87% |
Jumlah ekuiti | 211.32B | — |
Syer tertunggak | 42.81J | — |
Harga kepada buku | 0.74 | — |
Pulangan pada aset | 2.41% | — |
Pulangan pada modal | 2.83% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (JPY) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | 3.59B | 35.05% |
Tunai daripada operasi | — | — |
Tunai daripada pelaburan | — | — |
Tunai daripada pembiayaan | — | — |
Perubahan bersih dalam tunai | — | — |
Aliran tunai bebas | — | — |
Perihal
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
Diasaskan
9 Ogo 1946
Ibu pejabat
Tapak web
Pekerja
1,779
